Search research articles
Contact Us
Filters
Showing results (1001-1010 of 1,033) with videos related to
Page
of 104
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Plos One
|
June 16, 2022
Point-prevalence survey of antibiotic use at three public referral hospitals in Kenya
Sylvia Omulo, Margaret Oluka, Loice Achieng, et al.
Molecular Biology and Evolution
|
February 22, 2021
Adaptive Admixture of HLA Class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians
Zhihui Deng, Jianxin Zhen, Genelle F Harrison, et al.
ESMO Open
|
June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
A Lamarca, D H Palmer, H S Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2004
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer
Daniel H Palmer, Vivien Mautner, Darius Mirza, et al.
Journal of Women'S Health (2002)
|
March 3, 2025
Associations Between U.S. Women's Toileting Behaviors and Lower Urinary Tract Symptoms: A Cross-Sectional Analysis of RISE for HEALTH Study Data
Amanda Berry, Sonya S Brady, Kathryn L Burgio, et al.
Scientific Reports
|
December 24, 2022
Prevalence of colonization with multidrug-resistant bacteria in communities and hospitals in Kenya
Teresa Ita, Ulzii-Orshikh Luvsansharav, Rachel M Smith, et al.
The Lancet. Oncology
|
April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Cancer Research Communications
|
August 23, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Torben Ek, Raghda R Ibrahim, Hartmut Vogt, et al.
The Lancet. Oncology
|
March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Gary Middleton, Daniel H Palmer, William Greenhalf, et al.
Page
of 104
Search research articles
Search
Showing results (1001-1010 of 1,033) with videos related to
Sort By:
Page
of 104
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Plos One
|
June 16, 2022
Point-prevalence survey of antibiotic use at three public referral hospitals in Kenya
Sylvia Omulo, Margaret Oluka, Loice Achieng, et al.
Molecular Biology and Evolution
|
February 22, 2021
Adaptive Admixture of HLA Class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians
Zhihui Deng, Jianxin Zhen, Genelle F Harrison, et al.
ESMO Open
|
June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial
A Lamarca, D H Palmer, H S Wasan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2004
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer
Daniel H Palmer, Vivien Mautner, Darius Mirza, et al.
Journal of Women'S Health (2002)
|
March 3, 2025
Associations Between U.S. Women's Toileting Behaviors and Lower Urinary Tract Symptoms: A Cross-Sectional Analysis of RISE for HEALTH Study Data
Amanda Berry, Sonya S Brady, Kathryn L Burgio, et al.
Scientific Reports
|
December 24, 2022
Prevalence of colonization with multidrug-resistant bacteria in communities and hospitals in Kenya
Teresa Ita, Ulzii-Orshikh Luvsansharav, Rachel M Smith, et al.
The Lancet. Oncology
|
April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Cancer Research Communications
|
August 23, 2024
Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis
Torben Ek, Raghda R Ibrahim, Hartmut Vogt, et al.
The Lancet. Oncology
|
March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Gary Middleton, Daniel H Palmer, William Greenhalf, et al.
Page
of 104